ERYC SPRINKLES Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Eryc Sprinkles, and what generic alternatives are available?
Eryc Sprinkles is a drug marketed by Hospira and is included in one NDA.
The generic ingredient in ERYC SPRINKLES is erythromycin. There are one hundred and three drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Eryc Sprinkles
A generic version of ERYC SPRINKLES was approved as erythromycin by TORRENT on July 6th, 2020.
US Patents and Regulatory Information for ERYC SPRINKLES
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospira | ERYC SPRINKLES | erythromycin | CAPSULE, DELAYED REL PELLETS;ORAL | 050593-001 | Jul 22, 1985 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
